Hypertension Excellence Centre-ESH, Department of Cardiology, LAIKO General Hospital, Athens, Greece.
2nd Department of Internal Medicine, Attikon General Hospital, Athens Medical School, Athens, Greece.
Am J Hypertens. 2020 Mar 13;33(3):207-213. doi: 10.1093/ajh/hpz157.
Sodium glucose cotransporter 2 (SGLT2) inhibitors represent a novel class of oral antihyperglycemic drugs that have been approved over the last decade for the management of type 2 diabetes mellitus. Except the glucose-lowering effects, robust evidence also suggests that SGLT2 inhibitors confer benefits in cardiovascular system. The purpose of this review was to investigate the effects of SGLT2 inhibitors across the spectrum of arterial hypertension.
钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂是一类新型的口服抗高血糖药物，在过去十年中已被批准用于 2 型糖尿病的治疗。除了降低血糖的作用外，大量证据还表明 SGLT2 抑制剂对心血管系统有益。本综述的目的是研究 SGLT2 抑制剂在动脉高血压谱中的作用。
